Dehu Dou

Dehu Dou

Auto-generated profile, based on publicly available information

Dehu Dou

Research Center of Clinical Pharmacology, China Pharmaceutical University, Nanjing, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2025 in SLAS Discovery
Verified
Journal Article
Open access
HRHaiwen Ruan
Haiwen Ruan
DDDehu Dou
Dehu Dou
JLJing Lu
Jing Lu
XXXia Xiao
Xia Xiao
XGXinjiang Gong
Xinjiang Gong
ZXZhang Xuefeng
Zhang Xuefeng
Oligonucleotide-based therapies, such as antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), represent a class of therapeutic agents that specifically target gene transcription or translation mechanisms through sequence specificity. These pharmaceuticals exhibit significant promise in the treatment of genetic disorders, including spinal muscular atrophy, as well as malignancies, viral infections, and metabolic diseases. Nonetheless, unintended toxicity continues to pose a considerable challenge and remain a critical safety concern in the development of oligonucleotide therapeutics (ONTs). Off-target toxicity may be caused by hybridization to sequences that are similar but not identical to the target, hybridization-independent sequence related, or sequence- and hybridization-independent effects. The effects may result in diminished transcript levels, decreased translation rates, or anomalous splicing, employing same molecular pathways and protein machinery as the desired on-target effects. Currently, there exists no established methodology for the systematic identification and evaluation of off-target toxicity, which may hinder the optimization of safety approaches. This review delineates significant nonclinical toxicities and clinical adverse effects by summarizing and analyzing approved oligonucleotides with their off-target assays, encompassing the limitations of nonclinical off-target effects and the potential off-target mechanisms. Plus, it discusses and emphasizes the factors that lead to the off target of ONTs, systematically offers approaches and workflows of preclinical assessments to enhance the transfer value of oligonucleotide therapies from nonclinical to clinical trials by managing unavoidable off-target effects.

1 October 2025 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
DDDehu Dou
Dehu Dou
JLJing Lu
Jing Lu
XCXijing Chen
Xijing Chen
XZXuefeng Zhang
Xuefeng Zhang

17 September 2025 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
DDDehu Dou
Dehu Dou
JLJing Lu
Jing Lu
PSPeixin Sangchen
Peixin Sangchen
CGChaorui Guo
Chaorui Guo
DLDeli Li
Deli Li
XCXijing Chen
Xijing Chen

10 October 2025 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
DDDehu Dou
Dehu Dou
JLJing Lu
Jing Lu
DLDeli Li
Deli Li
FHFengxia He
Fengxia He
XZXi Zhu
Xi Zhu
XCXijing Chen
Xijing Chen

18 July 2025 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
DDDehu Dou
Dehu Dou
JLJing Lu
Jing Lu
AFAli Fan
Ali Fan
XCXijing Chen
Xijing Chen

28 May 2026 in Pharmaceutical Research
Verified
Journal Article
Closed access
DDDehu Dou
Dehu Dou
JLJing Lu
Jing Lu
DLDeli Li
Deli Li
FHFengxia He
Fengxia He
XZXi Zhu
Xi Zhu
XCXijing Chen
Xijing Chen